Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection

David Boutolleau; Ana Canestri; Sonia Burrel; Marc Wirden; Sophie Seang; Cyril Clavel-Osorio; Anne-Geneviève Marcelin; Christine Katlama; Henri Agut

doi:10.1016/j.jcv.2012.02.008

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection

J Clin Virol. 2012 Jun;54(2):194-6. doi: 10.1016/j.jcv.2012.02.008. Epub 2012 Mar 6.

Authors

David Boutolleau¹, Ana Canestri, Sonia Burrel, Marc Wirden, Sophie Seang, Cyril Clavel-Osorio, Anne-Geneviève Marcelin, Christine Katlama, Henri Agut

Affiliation

¹ UPMC Univ Paris 06, ER1 DETIV, F-75013 Paris, France. [email protected]

PMID: 22398036
DOI: 10.1016/j.jcv.2012.02.008

Abstract

Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication. We describe herein the emergence of CMV resistance to FOS in a 54-year-old man receiving FOS salvage therapy because of multidrug-resistant HIV-1 infection. Oral valganciclovir (VGCV) treatment allowed subsequently the improvement of FOS-resistant CMV infection.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antiretroviral Therapy, Highly Active / methods
Antiviral Agents / pharmacology*
Cytomegalovirus / drug effects*
Cytomegalovirus Infections / complications
Cytomegalovirus Infections / virology*
Drug Resistance, Multiple, Viral*
Drug Resistance, Viral*
Foscarnet / pharmacology*
HIV Infections / complications
HIV Infections / drug therapy*
HIV-1 / drug effects
Humans
Male
Middle Aged
Salvage Therapy / methods

Substances

Antiviral Agents
Foscarnet